Delivery Order 36F79720D0180-36C26226F0314
Award Date 7/20/26
Potential Completion Date 12/31/26
Potential Value $823K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92161, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Veterans Integrated Service Network 1 issued a delivery order to Novartis Pharmaceuticals Corporation on September 15, 2025, for PLUVICTO (Lutetium Lu-177 Vipivotide Tetra), a radiopharmaceutical oncology treatment, with a ceiling value of $810,280.80 under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). Place of performance is West Haven, CT. The order is firm fixed price with an ultimate completion date of September 14, 2026. No small business set-aside applies. Novartis...
- Novartis Pharmaceuticals Corporation received a $813,476.16 firm fixed-price delivery order from Veterans Integrated Service Network 2 (VISN 2) for PLUVICTO (Lutetium Lu-177 Vipivotide Tetra), a specialized radiopharmaceutical cancer therapy product. The delivery order, issued on November 1, 2025, with an ultimate completion date of October 31, 2026, falls under Novartis' existing Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract vehicle. The place of performance is East...
- Novartis Pharmaceuticals Corporation has been awarded a delivery order valued at approximately $685,885 by Veterans Integrated Service Network 12 (VISN 12) for PLUVICTO (Lutetium Lu-177 Vipivotide Tetra), a specialized radiopharmaceutical used in advanced cancer therapy. This firm fixed-price delivery order, issued on February 1, 2026, with a completion date of July 31, 2026, is being fulfilled from the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The award carries no small...
- The Department of Veterans Affairs, Veterans Integrated Service Network 10, awarded a delivery order valued at $617,296.68 to Novartis Pharmaceuticals Corporation on January 20, 2026, for the supply of PLUVICTO (Lutetium Lu-177 Vipivotide Tetra), a specialized radiopharmaceutical cancer therapy product. This firm fixed-price delivery order, with completion expected by June 30, 2026, was issued without a small business set-aside designation and falls under Novartis' existing Pharmaceuticals and...
- Novartis Pharmaceuticals Corporation received a delivery order award from Veterans Integrated Service Network 21 (VISN 21) for PLUVICTO (Lutetium Lu-177 Vipivotide Tetra), a specialized radiopharmaceutical used in advanced cancer treatment. The delivery order, awarded October 1, 2025, carries a ceiling value of $1.63M and a firm fixed-price structure under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The contract has no small business set-aside designation, allowing...
- Novartis Pharmaceuticals Corporation received a $4.73M firm fixed-price delivery order from Veterans Integrated Service Network 8 (VISN 8) for PLUVICTO (Lutetium Lu-177 Vipivotide Tetra), a specialized radiopharmaceutical used in advanced cancer treatment. Awarded on February 24, 2026, with an ultimate completion date of August 31, 2026, this delivery order carries no small business set-aside designation. The contract will be performed at Novartis' facility in East Hanover, New Jersey,...
- Novartis Pharmaceuticals Corporation received a $857,356.50 firm fixed-price delivery order for PLUVICTO (Lutetium Lu-177 Vipivotide Tetra), a specialized radiopharmaceutical cancer therapy, from Veterans Integrated Service Network 17 through the Department of Veterans Affairs. The delivery order, designated OY1, was awarded on July 1, 2025, with an ultimate completion date of June 30, 2027, and will be performed at the company's East Hanover, New Jersey facility. No small business set-aside was...
- Novartis Pharmaceuticals Corporation has been awarded a delivery order by Veterans Integrated Service Network 12 (VISN 12) for the supply of PLUVICTO (Lutetium Lu-177 Vipivotide Tetra), a specialized radiopharmaceutical used in advanced cancer therapy. The delivery order, valued at $2.18M, is structured as a firm fixed-price contract with a base period plus one option year, extending through August 31, 2027. This award represents a call against Novartis' existing Blanket Purchase Agreement...
- Novartis Pharmaceuticals Corporation received a $2.42M firm fixed-price delivery order from Veterans Integrated Service Network 10 (VISN 10) on February 1, 2026, for the supply of radiopharmaceuticals PLUVICTO (Lutetium Lu-177 Vipivotide Tetra) and LUTATHERA (Lutetium Lu-177 dotatate). The contract, which extends through December 31, 2026, will be performed in East Hanover, New Jersey, and was awarded without small business set-aside protections. This delivery order is issued under Novartis'...
- Novartis Pharmaceuticals Corporation was awarded a delivery order valued at $4.16M by Veterans Integrated Service Network 17 (VISN 17) for the supply of LU177 radiopharmaceutical products, specifically PLUVICTO (Lutetium Lu-177 Vipivotide Tetra) and LUTATHERA (Lutetium Lu-177 dotatate). The contract, issued on February 7, 2026, with completion targeted for February 6, 2027, operates under a firm fixed-price structure without small business set-aside designation. This delivery order is issued...